Search

Your search keyword '"Green, Damian"' showing total 31 results
Start Over Author "Green, Damian" Publisher american association for cancer research (aacr)
31 results on '"Green, Damian"'

1. Data from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

Author

Orozco, Johnnie J., primary, Vo, Phuong T., primary, Gooley, Ted A., primary, Haaf, Robyn L., primary, Lundberg, Sally J., primary, Hamlin, Donald K., primary, Wilbur, D. Scott, primary, Matesan, Manuela C., primary, Fisher, Darrell R., primary, Gopal, Ajay K., primary, Green, Damian J., primary, Pagel, John M., primary, and Sandmaier, Brenda M., primary

Published
2024
Full Text
View/download PDF

2. Supplementary Fig S2 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

Author

Orozco, Johnnie J., primary, Vo, Phuong T., primary, Gooley, Ted A., primary, Haaf, Robyn L., primary, Lundberg, Sally J., primary, Hamlin, Donald K., primary, Wilbur, D. Scott, primary, Matesan, Manuela C., primary, Fisher, Darrell R., primary, Gopal, Ajay K., primary, Green, Damian J., primary, Pagel, John M., primary, and Sandmaier, Brenda M., primary

Published
2024
Full Text
View/download PDF

3. Supplementary Table S1 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

Author

Orozco, Johnnie J., primary, Vo, Phuong T., primary, Gooley, Ted A., primary, Haaf, Robyn L., primary, Lundberg, Sally J., primary, Hamlin, Donald K., primary, Wilbur, D. Scott, primary, Matesan, Manuela C., primary, Fisher, Darrell R., primary, Gopal, Ajay K., primary, Green, Damian J., primary, Pagel, John M., primary, and Sandmaier, Brenda M., primary

Published
2024
Full Text
View/download PDF

4. Targeted Radiation Delivery Before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-Term Survivors

Author

Orozco, Johnnie J., primary, Vo, Phuong T., additional, Gooley, Ted A., additional, Haaf, Robyn L., additional, Lundberg, Sally J., additional, Hamlinn, Donald K., additional, Wilbur, D. Scott., additional, Matesan, Manuela C., additional, Fisher, Darrell R., additional, Gopal, Ajay K., additional, Green, Damian J., additional, Pagel, John M., additional, and Sandmaier, Brenda M., additional

Published
2023
Full Text
View/download PDF

5. Supplementary Materials and Methods from Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA

Author

Orozco, Johnnie J., primary, Kenoyer, Aimee L., primary, Lin, Yukang, primary, O'Steen, Shyril, primary, Guel, Rosario, primary, Nartea, Margaret E., primary, Hernandez, Alexandra H., primary, Hylarides, Mark D., primary, Fisher, Darrell R., primary, Balkin, Ethan R., primary, Hamlin, Donald K., primary, Wilbur, D. Scott, primary, Orcutt, Kelly D., primary, Wittrup, K. Dane, primary, Green, Damian J., primary, Gopal, Ajay K., primary, Till, Brian G., primary, Sandmaier, Brenda, primary, Press, Oliver W., primary, and Pagel, John M., primary

Published
2023
Full Text
View/download PDF

6. Data from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

Author

Rufener, Gregory A., primary, Press, Oliver W., primary, Olsen, Philip, primary, Lee, Sang Yun, primary, Jensen, Michael C., primary, Gopal, Ajay K., primary, Pender, Barbara, primary, Budde, Lihua E., primary, Rossow, Jeffrey K., primary, Green, Damian J., primary, Maloney, David G., primary, Riddell, Stanley R., primary, and Till, Brian G., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figures 1 through 10 from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

Author

Rufener, Gregory A., primary, Press, Oliver W., primary, Olsen, Philip, primary, Lee, Sang Yun, primary, Jensen, Michael C., primary, Gopal, Ajay K., primary, Pender, Barbara, primary, Budde, Lihua E., primary, Rossow, Jeffrey K., primary, Green, Damian J., primary, Maloney, David G., primary, Riddell, Stanley R., primary, and Till, Brian G., primary

Published
2023
Full Text
View/download PDF

8. Data from Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Author

Green, Damian J., primary, Frayo, Shani L., primary, Lin, Yukang, primary, Hamlin, Donald K., primary, Fisher, Darrell R., primary, Frost, Sofia H.L., primary, Kenoyer, Aimee L., primary, Hylarides, Mark D., primary, Gopal, Ajay K., primary, Gooley, Theodore A., primary, Orozco, Johnnie J., primary, Till, Brian G., primary, O'Steen, Shyril, primary, Orcutt, Kelly D., primary, Wilbur, D. Scott, primary, Wittrup, K. Dane, primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

9. Table S1 from Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

Author

O'Steen, Shyril, primary, Green, Damian J., primary, Gopal, Ajay K., primary, Orozco, Johnnie J., primary, Kenoyer, Aimee L., primary, Lin, Yukang, primary, Wilbur, D. Scott, primary, Hamlin, Donald K., primary, Fisher, Darrell R., primary, Hylarides, Mark D., primary, Gooley, Theodore A., primary, Waltman, Amelia, primary, Till, Brian G., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

10. Data from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Author

Park, Steven I., primary, Shenoi, Jaideep, primary, Frayo, Shani M., primary, Hamlin, Donald K., primary, Lin, Yukang, primary, Wilbur, D. Scott, primary, Stayton, Patrick S., primary, Orgun, Nural, primary, Hylarides, Mark, primary, Buchegger, Franz, primary, Kenoyer, Aimee L., primary, Axtman, Amanda, primary, Gopal, Ajay K., primary, Green, Damian J., primary, Pagel, John M., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 1 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Author

Park, Steven I., primary, Shenoi, Jaideep, primary, Frayo, Shani M., primary, Hamlin, Donald K., primary, Lin, Yukang, primary, Wilbur, D. Scott, primary, Stayton, Patrick S., primary, Orgun, Nural, primary, Hylarides, Mark, primary, Buchegger, Franz, primary, Kenoyer, Aimee L., primary, Axtman, Amanda, primary, Gopal, Ajay K., primary, Green, Damian J., primary, Pagel, John M., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

12. Data from Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

Author

O'Steen, Shyril, primary, Green, Damian J., primary, Gopal, Ajay K., primary, Orozco, Johnnie J., primary, Kenoyer, Aimee L., primary, Lin, Yukang, primary, Wilbur, D. Scott, primary, Hamlin, Donald K., primary, Fisher, Darrell R., primary, Hylarides, Mark D., primary, Gooley, Theodore A., primary, Waltman, Amelia, primary, Till, Brian G., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 1 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Author

Park, Steven I., primary, Shenoi, Jaideep, primary, Frayo, Shani M., primary, Hamlin, Donald K., primary, Lin, Yukang, primary, Wilbur, D. Scott, primary, Stayton, Patrick S., primary, Orgun, Nural, primary, Hylarides, Mark, primary, Buchegger, Franz, primary, Kenoyer, Aimee L., primary, Axtman, Amanda, primary, Gopal, Ajay K., primary, Green, Damian J., primary, Pagel, John M., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 2 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Author

Park, Steven I., primary, Shenoi, Jaideep, primary, Frayo, Shani M., primary, Hamlin, Donald K., primary, Lin, Yukang, primary, Wilbur, D. Scott, primary, Stayton, Patrick S., primary, Orgun, Nural, primary, Hylarides, Mark, primary, Buchegger, Franz, primary, Kenoyer, Aimee L., primary, Axtman, Amanda, primary, Gopal, Ajay K., primary, Green, Damian J., primary, Pagel, John M., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

15. Data from A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies

Author

Green, Damian J., primary, Orgun, Nural N., primary, Jones, Jon C., primary, Hylarides, Mark D., primary, Pagel, John M., primary, Hamlin, Donald K., primary, Wilbur, D.S., primary, Lin, Yukang, primary, Fisher, Darrell R., primary, Kenoyer, Aimee L., primary, Frayo, Shani L., primary, Gopal, Ajay K., primary, Orozco, Johnnie J., primary, Gooley, Theodore A., primary, Wood, Brent L., primary, Bensinger, William I., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

16. Supplemental Figure 1. In vitro phantom containing 100 μCi 177Lu. from In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model

Author

Balkin, Ethan R., primary, Kenoyer, Aimee, primary, Orozco, Johnnie J., primary, Hernandez, Alexandra, primary, Shadman, Mazyar, primary, Fisher, Darrell R., primary, Green, Damian J., primary, Hylarides, Mark D., primary, Press, Oliver W., primary, Wilbur, D. Scott, primary, and Pagel, John M., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figures 1 and 2 and Supplementary Methods from A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies

Author

Green, Damian J., primary, Orgun, Nural N., primary, Jones, Jon C., primary, Hylarides, Mark D., primary, Pagel, John M., primary, Hamlin, Donald K., primary, Wilbur, D.S., primary, Lin, Yukang, primary, Fisher, Darrell R., primary, Kenoyer, Aimee L., primary, Frayo, Shani L., primary, Gopal, Ajay K., primary, Orozco, Johnnie J., primary, Gooley, Theodore A., primary, Wood, Brent L., primary, Bensinger, William I., primary, and Press, Oliver W., primary

Published
2023
Full Text
View/download PDF

18. Data from In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model

Author

Balkin, Ethan R., primary, Kenoyer, Aimee, primary, Orozco, Johnnie J., primary, Hernandez, Alexandra, primary, Shadman, Mazyar, primary, Fisher, Darrell R., primary, Green, Damian J., primary, Hylarides, Mark D., primary, Press, Oliver W., primary, Wilbur, D. Scott, primary, and Pagel, John M., primary

Published
2023
Full Text
View/download PDF

19. Supplemental Figure 2. Cerenkov Light Images of excised organs. from In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model

Author

Balkin, Ethan R., primary, Kenoyer, Aimee, primary, Orozco, Johnnie J., primary, Hernandez, Alexandra, primary, Shadman, Mazyar, primary, Fisher, Darrell R., primary, Green, Damian J., primary, Hylarides, Mark D., primary, Press, Oliver W., primary, Wilbur, D. Scott, primary, and Pagel, John M., primary

Published
2023
Full Text
View/download PDF

20. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90 Y-DOTA

Author

Massachusetts Institute of Technology. Department of Biological Engineering, Orozco, Johnnie J, Kenoyer, Aimee L, Lin, Yukang, O'Steen, Shyril, Guel, Rosario, Nartea, Margaret E, Hernandez, Alexandra H, Hylarides, Mark D, Fisher, Darrell R, Balkin, Ethan R, Hamlin, Donald K, Wilbur, D Scott, Orcutt, Kelly D, Wittrup, K Dane, Green, Damian J, Gopal, Ajay K, Till, Brian G, Sandmaier, Brenda, Press, Oliver W, Pagel, John M, Massachusetts Institute of Technology. Department of Biological Engineering, Orozco, Johnnie J, Kenoyer, Aimee L, Lin, Yukang, O'Steen, Shyril, Guel, Rosario, Nartea, Margaret E, Hernandez, Alexandra H, Hylarides, Mark D, Fisher, Darrell R, Balkin, Ethan R, Hamlin, Donald K, Wilbur, D Scott, Orcutt, Kelly D, Wittrup, K Dane, Green, Damian J, Gopal, Ajay K, Till, Brian G, Sandmaier, Brenda, Press, Oliver W, and Pagel, John M

Abstract

© 2020 American Association for Cancer Research. Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited the use of PRIT with an anti-CD45 antibody streptavidin conjugate and radiolabeled DOTA-biotin. To overcome these limitations we designed anti-murine and anti-human CD45 bispecific antibody constructs using 30F11 and BC8 antibodies, respectively, combined with an anti-yttrium (Y)-DOTA single-chain variable fragment (C825) to capture a radiolabeled ligand. The bispecific construct targeting human CD45 (BC8-Fc-C825) had high uptake in leukemia HEL xenografts [7.8 = 0.02% percent injected dose/gram of tissue (% ID/g)]. Therapy studies showed that 70% of mice with HEL human xenografts treated with BC8-Fc-C825 followed by 44.4 MBq (1,200 mCi) of 90Y-DOTA-biotin survived at least 170 days after therapy, while all nontreated controls required euthanasia because of tumor progression by day 32. High uptake at sites of leukemia (spleen and bone marrow) was also seen with 30F11-IgG1-C825 in a syngeneic disseminated SJL murine leukemia model (spleen, 9.0 = 1.5% ID/g and bone marrow, 8.1 = 1.2% ID/g), with minimal uptake in all other normal organs (<0.5% ID/g) at 24 hours after 90Y-DOTA injections. SJL leukemia mice treated with the bispecific 30F11-IgG1-C825 and 29.6 MBq (800 mCi) of 90Y-DOTA-biotin had a survival advantage compared with untreated leukemic mice (median, 43 vs. 30 days, respectively; P < 0.0001). These data suggest bispecific antibody–mediated PRIT may be highly effective for leukemia therapy and translation to human studies.

Published
2021

21. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Author

Massachusetts Institute of Technology. Department of Chemical Engineering, Massachusetts Institute of Technology. Department of Biological Engineering, Green, Damian J., Frayo, Shani L., Lin, Yukang, Hamlin, Donald K., Fisher, Darrell R., Frost, Sofia H.L., Kenoyer, Aimee L., Hylarides, Mark D., Gopal, Ajay K., Gooley, Theodore A., Orozco, Johnnie J., Till, Brian G., O'Steen, Shyril, Orcutt, Kelly Davis, Wilbur, D. Scott, Wittrup, Karl Dane, Press, Oliver W., Massachusetts Institute of Technology. Department of Chemical Engineering, Massachusetts Institute of Technology. Department of Biological Engineering, Green, Damian J., Frayo, Shani L., Lin, Yukang, Hamlin, Donald K., Fisher, Darrell R., Frost, Sofia H.L., Kenoyer, Aimee L., Hylarides, Mark D., Gopal, Ajay K., Gooley, Theodore A., Orozco, Johnnie J., Till, Brian G., O'Steen, Shyril, Orcutt, Kelly Davis, Wilbur, D. Scott, Wittrup, Karl Dane, and Press, Oliver W.

Abstract

Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy in model systems, but SA immunogenicity and interference by endogenous biotin may complicate clinical translation of this approach. In this study, we engineered a bispecific fusion protein (FP) that evades the limitations imposed by this system. Briefly, one arm of the FP was an anti-human CD20 antibody (2H7), with the other arm of the FP an anti-chelated radiometal trap for a radiolabeled ligand (yttrium[Y]-DOTA) captured by a very high-affinity anti-Y-DOTA scFv antibody (C825). Head-to-head biodistribution experiments comparing SA-biotin and bispecific FP (2H7-Fc-C825) PRIT in murine subjects bearing human lymphoma xenografts demonstrated nearly identical tumor targeting by each modality at 24 hours. However, residual radioactivity in the blood and normal organs was consistently higher following administration of 1F5-SA compared with 2H7-Fc-C825. Consequently, tumor-to-normal tissue ratios of distribution were superior for 2H7-Fc-C825 (P < 0.0001). Therapy studies in subjects bearing either Ramos or Granta subcutaneous lymphomas demonstrated that 2H7-Fc-C825 PRIT is highly effective and significantly less myelosuppressive than 1F5-SA (P < 0.0001). All animals receiving optimal doses of 2H7-Fc-C825 followed by 90Y-DOTA were cured by 150 days, whereas the growth of tumors in control animals progressed rapidly with complete morbidity by 25 days. In addition to demonstrating reduced risk of immunogenicity and an absence of endogenous biotin interference, our findings offer a preclinical proof of concept for the preferred use of bispecific PRIT in future clinical trials, due to a slightly superior biodistribution profile, less myelosuppression, and superior efficacy.

Published
2020

22. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA

Author

Orozco, Johnnie J., primary, Kenoyer, Aimee L., additional, Lin, Yukang, additional, O'Steen, Shyril, additional, Guel, Rosario, additional, Nartea, Margaret E., additional, Hernandez, Alexandra H., additional, Hylarides, Mark D., additional, Fisher, Darrell R., additional, Balkin, Ethan R., additional, Hamlin, Donald K., additional, Wilbur, D. Scott, additional, Orcutt, Kelly D., additional, Wittrup, K. Dane, additional, Green, Damian J., additional, Gopal, Ajay K., additional, Till, Brian G., additional, Sandmaier, Brenda, additional, Press, Oliver W., additional, and Pagel, John M., additional

Published
2020
Full Text
View/download PDF

24. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

Author

O'Steen, Shyril, primary, Green, Damian J., additional, Gopal, Ajay K., additional, Orozco, Johnnie J., additional, Kenoyer, Aimee L., additional, Lin, Yukang, additional, Wilbur, D. Scott, additional, Hamlin, Donald K., additional, Fisher, Darrell R., additional, Hylarides, Mark D., additional, Gooley, Theodore A., additional, Waltman, Amelia, additional, Till, Brian G., additional, and Press, Oliver W., additional

Published
2017
Full Text
View/download PDF

26. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Author

Green, Damian J., primary, Frayo, Shani L., additional, Lin, Yukang, additional, Hamlin, Donald K., additional, Fisher, Darrell R., additional, Frost, Sofia H.L., additional, Kenoyer, Aimee L., additional, Hylarides, Mark D., additional, Gopal, Ajay K., additional, Gooley, Theodore A., additional, Orozco, Johnnie J., additional, Till, Brian G., additional, O'Steen, Shyril, additional, Orcutt, Kelly D., additional, Wilbur, D. Scott, additional, Wittrup, K. Dane, additional, and Press, Oliver W., additional

Published
2016
Full Text
View/download PDF

27. Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

Author

Rufener, Gregory A., primary, Press, Oliver W., additional, Olsen, Philip, additional, Lee, Sang Yun, additional, Jensen, Michael C., additional, Gopal, Ajay K., additional, Pender, Barbara, additional, Budde, Lihua E., additional, Rossow, Jeffrey K., additional, Green, Damian J., additional, Maloney, David G., additional, Riddell, Stanley R., additional, and Till, Brian G., additional

Published
2016
Full Text
View/download PDF

28. In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model

Author

Balkin, Ethan R., primary, Kenoyer, Aimee, additional, Orozco, Johnnie J., additional, Hernandez, Alexandra, additional, Shadman, Mazyar, additional, Fisher, Darrell R., additional, Green, Damian J., additional, Hylarides, Mark D., additional, Press, Oliver W., additional, Wilbur, D. Scott, additional, and Pagel, John M., additional

Published
2014
Full Text
View/download PDF

29. A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies

Author

Green, Damian J., primary, Orgun, Nural N., additional, Jones, Jon C., additional, Hylarides, Mark D., additional, Pagel, John M., additional, Hamlin, Donald K., additional, Wilbur, D.S., additional, Lin, Yukang, additional, Fisher, Darrell R., additional, Kenoyer, Aimee L., additional, Frayo, Shani L., additional, Gopal, Ajay K., additional, Orozco, Johnnie J., additional, Gooley, Theodore A., additional, Wood, Brent L., additional, Bensinger, William I., additional, and Press, Oliver W., additional

Published
2014
Full Text
View/download PDF

30. Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Author

Park, Steven I., primary, Shenoi, Jaideep, additional, Frayo, Shani M., additional, Hamlin, Donald K., additional, Lin, Yukang, additional, Wilbur, D. Scott, additional, Stayton, Patrick S., additional, Orgun, Nural, additional, Hylarides, Mark, additional, Buchegger, Franz, additional, Kenoyer, Aimee L., additional, Axtman, Amanda, additional, Gopal, Ajay K., additional, Green, Damian J., additional, Pagel, John M., additional, and Press, Oliver W., additional

Published
2011
Full Text
View/download PDF

31. Pretargeted Radioimmunotherapy for B-Cell Lymphomas

Author

Green, Damian J., primary, Pagel, John M., additional, Pantelias, Anastasia, additional, Hedin, Nathan, additional, Lin, Yukang, additional, Wilbur, D. Scott, additional, Gopal, Ajay, additional, Hamlin, Donald K., additional, and Press, Oliver W., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results